MGCD516

DRUG2 trials

Sponsors

Mirati Therapeutics Inc., Columbia University

Conditions

Advanced CancerLiposarcomaMetastatic Liposarcoma

Phase 1

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

CompletedNCT02219711

Mirati Therapeutics Inc.Advanced Cancer

Start: 2014-08-31End: 2022-04-27Updated: 2023-03-06

Phase 2

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

CompletedNCT02978859

Columbia UniversityLiposarcoma, Metastatic Liposarcoma

Start: 2016-11-30End: 2021-12-20Updated: 2024-07-18

Related Papers

Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

Future Oncology2024-11-081 citations

Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer

Investigational New Drugs2024-08-211 citations

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.

2022-06-2932 citations

A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.

Journal of Clinical Oncology2021-05-203 citations

Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL

Annals of Oncology2018-10-01

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

Journal of Clinical Oncology2018-05-204 citations

Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.

Journal of Clinical Oncology2017-05-203 citations

A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.

Journal of Clinical Oncology2016-05-2010 citations

A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-203 citations